Preclinical and clinical studies have evaluated Eritoran tetrasodium, a compound that interferes with TLR4/MD-2/LPS, inhibiting the LPS-induced release of TNF-α, IL-β and IL-6, thus limiting excessive inflammation associated with TLR4 activation, as a potential therapeutic for sepsis. The gene discussed is TLR4; the disease is Sepsis.